Replacement therapies in hemophilia A and B – Efficacy of extended half-life products

Chairs: David Lillicrap (Canada), Pier Mannuccio Mannucci (Italy)

08.30

Real life data: real benefits. What have we achieved?
Pratima Chowdari (UK)

09.00

How to optimize the use of extended half-life products (PK analysis)
Alfonso Iorio (Canada)

Safety of replacement therapies (standard and novel) (part I)

Chairs: Nicola Ciavarella (Italy), Maria Elisa Mancuso (Italy)

09.30

Which bleeding phenotype can we expect in severe hemophilia A previously untreated patients treated with non replacement therapies?
Karin Fijn van Draat (The Netherlands)

10.00

How safety of novel anti-hemophilic drugs should be approached. Known and unknown adverse effects
Flora Peyvandi (Italy)

10.30

Are Fc – FVIII products less immunogenic? New clinical data?
Christoph Königs (Germany)

11.00

Break

Safety of replacement therapies (standard and novel) (part II)

Chairs: Giovanni Di Minno (Italy), Flora Peyvandi (Italy)

11.30

Long-term side-effects of pegylated products: facts or fancies?
Silvio Garattini (Italy)

12.00

European pharmacovigilance of new products (with special emphasis on pegylated products)
Anneliese Hilger (EMA, Germany)

12.30

Immunogenicity of subcutaneous and intravenous drugs
David Lillicrap (Canada)

13.00

Bayer Lunch Satellite Symposium
TBA

14.00

Takeda Satellite Symposium
TBA

15.00

Kedrion Satellite Lecture
TBA

15.30

Break

16.00

Keynote Lecture “Choice of assays for novel anti-hemophilic therapies”
Armando Tripodi (Italy)

The role of von Willebrand factor in factor VIII immunogenicity

Chair: Giancarlo Castaman (Italy)

16.30

FVIII peptide presentation to the immune system; modulation by von Willebrand factor
Jan Voorberg (The Netherlands)

17.00

High von Willebrand factor affinity FVIII and immunogenicity
Peter Lenting (France)

17.30

Walking Poster Session